Compare TXMD & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXMD | NSRX |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | Israel |
| Employees | N/A | 7 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 25.8M |
| IPO Year | 2012 | N/A |
| Metric | TXMD | NSRX |
|---|---|---|
| Price | $1.98 | $3.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | 22.6K | ★ 130.0K |
| Earning Date | 05-12-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.68 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,761,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 35.25 | N/A |
| 52 Week Low | $0.98 | $1.98 |
| 52 Week High | $2.95 | $9.99 |
| Indicator | TXMD | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.25 | 51.17 |
| Support Level | $1.94 | $2.16 |
| Resistance Level | $2.05 | $4.49 |
| Average True Range (ATR) | 0.12 | 0.45 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 12.50 | 30.77 |
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.